header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-24269
Fish name: AB + MO1-mpi
Genotype: AB
Targeting Reagent: MO1-mpi
HUMAN DISEASE MODELED by AB + MO1-mpi
Human Disease Conditions Citations
congenital disorder of glycosylation type I standard conditions Chu et al., 2013
GENE EXPRESSION
Gene expression in AB + MO1-mpi
Reporter gene expression No data available
PHENOTYPE
Phenotype in AB + MO1-mpi
Phenotype Conditions Figures
apoptotic process increased occurrence, abnormal standard conditions Fig. 3 with image from DeRossi et al., 2017
dolichol-linked oligosaccharide biosynthetic process disrupted, abnormal standard conditions Fig. 2 with image from Chu et al., 2013
eye decreased size, abnormal standard conditions Fig. 3 with imageFig. 6 with image from DeRossi et al., 2017
Fig. 3 with image from Chu et al., 2013
eye size, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
forebrain decreased size, abnormal standard conditions Fig. 3 with image from Chu et al., 2013
glycolytic process decreased process quality, abnormal standard conditions Fig. 5 from DeRossi et al., 2017
head decreased size, abnormal standard conditions Fig. 3 with imageFig. 6 with image from DeRossi et al., 2017
head size, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
liver decreased size, abnormal standard conditions Fig. 3 with imageFig. 6 with image from DeRossi et al., 2017
liver size, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
mandibular arch skeleton malformed, abnormal standard conditions Fig. 3 with image from Chu et al., 2013
mandibular arch skeleton morphology, abnormal standard conditions Fig. 3 with imageFig. 6 with image from DeRossi et al., 2017
mandibular arch skeleton morphology, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
oligosaccharide-lipid intermediate biosynthetic process disrupted, abnormal standard conditions Fig. 2 with image from Chu et al., 2013
pericardium edematous, abnormal standard conditions Fig. 3 with imageFig. 6 with image from DeRossi et al., 2017
Fig. 3 with image from Chu et al., 2013
pericardium edematous, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
post-vent region curved, abnormal standard conditions Fig. 3 with image from Chu et al., 2013
whole organism tp53 expression amount, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 6 with image from DeRossi et al., 2017
whole organism tp53 expression amount, ameliorated chemical treatment: OSMI-1 Fig. 7 from DeRossi et al., 2017
whole organism Ab1-ogt labeling amount, ameliorated chemical treatment: 6-diazo-5-oxo-L-norleucine Fig. 7 from DeRossi et al., 2017
whole organism Ab2-ogt labeling amount, ameliorated chemical treatment: OSMI-1 Fig. 7 from DeRossi et al., 2017
whole organism dead, abnormal standard conditions Fig. 1 with image from Chu et al., 2013
whole organism decreased life span, abnormal standard conditions Fig. 3 with image from DeRossi et al., 2017
whole organism Ab2-ogt labeling increased amount, abnormal control Fig. 7 from DeRossi et al., 2017
whole organism Ab1-ogt labeling increased amount, abnormal standard conditions Fig. 7 from DeRossi et al., 2017
whole organism tp53 expression increased amount, abnormal standard conditions Fig. 3 with imageFig. 6 with imageFig. 7 from DeRossi et al., 2017
whole organism gfpt1 expression increased amount, abnormal control Fig. 6 with image from DeRossi et al., 2017
whole organism lactate decreased amount, abnormal standard conditions Fig. 5 from DeRossi et al., 2017

CITATIONS  (3)